Blog

• Primary hyperparathyroidism (PHPT) is seen in:
  • 0.1% to 0.5% of the adult population
• It is the most common cause of hypercalcemia (high calcium level) in the general population
• It is about three to four times more common in women than men (3:1 to 4:1)
• Patients are usually older, with an average age at presentation of 65 years (most cases are over 45 years)
• Learn more at:
  • https://collectedmed.com/index.php/article/article/demo_article_display/7545/83/2/1

#Arrangoiz #ParathyroidSurgeon #ParathyroidExpert #Hyperparathyroidism #PrimaryHyperparathyroidism #CancerSurgeon #EndocrineSurgery #Teacher #Surgeon #HeadandNeckSurgeon #SurgicalOncologist #ParathyroidAdenoma #Hypercalcemia #ElevatedCalciumLevels #Miami #MountSinaiMedicalCenter #MSMC #Mexico #Miami #Hialeah

👉Primary hyperparathyroidism most commonly occurs in women over the age of 45, however, ANYONE can develop it.

👉Therefore, anyone found to have high blood calcium levels should be evaluated for primary hyperparathyroidism.

#Arrangoiz #ParathyroidSurgeon #ParathyroidExpert #HeadandNeckSurgron #CheckYourCalcium #Miami #Mexico #MountSinaiMedicalCenter

👉Julio es el mes de la conciencia de la enfermedad paratiroidea!

👉Ayude a correr la voz y cuéntenos sobre su experiencia con la enfermedad paratiroidea.

👉 ¿Cómo se enteró del hiperparatiroidismo por primera vez? ¿Te diagnosticaste a ti mismo?

👉 ¿Pudiste diagnosticar a un amigo porque notaste las señales?

👉¡Cuéntanos sobre eso! Y si diagnosticaste a un amigo, envíelo a Rodrigo Arrangoiz, miembro de Sociedad Quirúrgica SC experto en el manejo del hiperparatiroidismo.

👉 Para obtener más información, vaya a http://www.hiperparatiroidismo.info

#Arrangoiz #ParathyroidExpert #ParathyroidSurgeon #Hiperparatiroidismo #Hipercalcemia #CheckYourCalcium #HeadandNeckSurgeon #EndocrineSurgeon #CirujanodeTumoresdeCabezayCuello #CirugiaEndocrina #CirugiaParatiroides #Hypercalcemia #Hyperparathyroidism #MountSinaiMedicalCenter #MSMC #Miami #Mexico

https://rodrigoarrangoizmd.wordpress.com/2019/07/04/julio-es-el-mes-de-la-conciencia-de-la-enfermedad-paratiroidea/

• Absolute contraindications to breast-conserving therapy include:
  • Prior radiation therapy to the breast or chest wall
  • Breast cancer early in pregnancy that would necessitate radiation therapy during pregnancy
  • Diffuse suspicious, malignant-appearing microcalcifications
  • Widespread disease that precludes negative margins with a satisfactory cosmetic result
• Retrospective reviews have shown that patients with collagen vascular diseases, specifically scleroderma:
  • Are at increased risk of radiation toxicities, even with modern techniques:
    • Therefore, the presence of scleroderma in this patient would be a relative contraindication for breast-conserving surgery in this patient
• There have been attempts to allow for breast-conserving surgery for selected patients with multifocal or multicentric disease:
  • Retrospective data suggest that although patients with multifocal or multicentric disease have increased risk of local recurrence and lower disease-free survival:
    • This finding is independent of the type of surgery performed
• The Alliance Z11102 study sought to prospectively determine whether patients with multiple ipsilateral breast cancers could safely undergo breast-conserving surgery:
  • Initial report in 2018 showed that breast-conserving surgery was feasible in 93% of patients:
    • This could be accomplished in one operation in 67% of cases
  • Data regarding local regional recurrence will be forthcoming
• Percutaneous ablation techniques such as cryoablation have promising potential for less-invasive management of breast cancer:
  • However, it is not recommended for multicentric disease
    • Large multicenter randomized clinical trials are needed to determine long-term efficacy
• References
  • Morrow M, Strom EA, Bassett LW, et al. Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin. 2002;52(5):277-300.
  • Breast cancer. National Comprehensive Cancer Network. 2018. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed September 9, 2018.
  • Zaremba N, Tamkus D, DiCarlo L, Herman J, Martin M, Bumpers HL. The dilemma of breast cancer treatment and existing collagen vascular disease: a case of scleroderma and review of the literature. Breast J. 2016;22(4):451-455.
  • Alm El-Din MA, Taghian AG. Breast conservation therapy for patients with locally advanced breast cancer. Semin Radiat Oncol. 2009;19(4):229-235.
  • Rosenkranz KM, Ballman K, McCall L, Kubicky C, Cuttino L, Le-Petross H, et al. The feasibility of breast-conserving surgery for multiple ipsilateral breast cancer: an initial report from ACOSOG Z11102 (Alliance) Trial. Ann Surg Oncol. 2018;25(10):2858-2866.
  • Lanza E, Palussiere J, Buy X, et al. Percutaneous image-guided cryoablation of breast cancer: a systematic review. J Vasc Interv Radiol. 2015;26(11):1652-1657.

• During the last decade, the necessity to perform axillary lymph node dissection (ALND) in clinically node-negative (cN0) patients with sentinel lymph node metastases (SLN+) is debated worldwide:
  • For patients with early breast cancer undergoing breast-conserving therapy (BCT), the ACOSOG-Z0011 trial has allowed for avoidance of unnecessary axillary lymph node dissection (ALND) in patients with 1–2 positive SLNs without compromising outcome
• The AMAROS trial investigated axillary radiotherapy (RT) versus ALND in patients with tumor-affected SLNs and showed that axillary RT could serve as a safe alternative to ALND with less morbidity
• Since 2012, both national and international guidelines suggest no further axillary treatment in patients meeting the Z0011 criteria or advocate regional radiotherapy (RT) as alternative therapy for ALND
• As patients treated with mastectomy were not included in the Z0011 and underrepresented in the AMAROS trial (with only 18% receiving mastectomy), evidence regarding the omission of ALND in this subset of patients is scarce
• In a Dutch study, which included 10,633 SLN+ patients with cT1 to T3 breast cancer who underwent mastectomy, the frequency of ALND decreased from 78% in 2009 to 10% in 2018. In patients with micrometastasis (N1mi) and isolated tumor cells (N0itc), ALND was soon abandoned, whereas 20% of patients diagnosed with ≥ N1a disease still underwent ALND at the end of the study period. Over the same period, postmastectomy radiotherapy (PMRT) increased from 4% to 49%. The increase of PMRT was merely seen in patients with ≥ N1a disease, from 2% to 70%, showing ALND is mostly replaced with PMRT in this group of patients. Besides the association between the degree of metastatic lymph node involvement and the performance of ALND, factors such as age, differentiation grade, tumor subtype, and hospital type affected the performance of ALND.
  • Factors associated with a higher chance of ALND performance were age < 40 years, lobular tumor type, basal-like tumor type, receiving chemotherapy, and treatment outside an academic institution
• The present data illustrate a strong reduction in the performance of ALND in SLN+ patients undergoing mastectomy. Recently, the results of the SINODAR-ONE trial, which included a substantial proportion of SLN+ patients treated by mastectomy (25%) showed excellent regional control among SLN+ patients who received no further local treatment
• Currently, there are two more ongoing trials evaluating the oncological safety of omitting axillary therapy in node-positive patients treated by mastectomy (the POSNOC trial and the SENOMAC trial)
• The observed tendency among clinicians to deescalate axillary surgery in the present study suggests that clinicians felt comfortable enough to avoid ALND in this subset of patients despite the limited evidence
• Long-term follow-up results from the aforementioned trials, possibly supported by outcome data from national registries, may not only provide more robust support for avoiding surgical staging of axillary lymph nodes, but may also help to better delineate the indication for radiotherapy when ALND is omitted
• References
  • Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918–26.Article PubMed PubMed Central Google Scholar
  • Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.Article PubMed PubMed Central Google Scholar
  • Tinterri C, Gentile D, Gatzemeier W, et al. Preservation of axillary lymph nodes compared with complete dissection in T1–2 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial. Ann Surg Oncol. 2022;29(9):5732–44.Article PubMed Google Scholar
  • Goyal A, Mann GB, Fallowfield L, et al. POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. BMJ Open. 2021;11(12):e054365.Article PubMed PubMed Central Google Scholar
  • de Boniface J, Frisell J, Andersson Y, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017;17(1):379.

• Single gland adenoma is the most common cause:
  • (75% to 90% of the cases of PHPT
• Lower pole adenomas (in relation to the thyroid):
  • Are more common than are upper pole adenomas
• The average size of a parathyroid gland is:
  • 6 mm X 4 mm X 2 mm
• The sizes of a parathyroid adenoma range from:
  • 1 cm to 3 cm
• The normal weight of a parathyroid gland is:
  • Approximately 40 mg to 50 mg
• The weight of parathyroid adenomas vary between:
  • 553.7 +/- 520.5 mg (range, 66-2536)
• Ectopic glands can be present in:
  • 4% to 16% of cases
• PHPT is caused by:
  • The enlargement of a single parathyroid gland or parathyroid adenoma in approximately 75% to 90% of the cases
  • Multi-disease is seen in 15% to 25% of the cases:
    • Double adenomas:
      • Are seen in approximately 2% to 12% of the cases
    • Triple adenomas:
      • In less than 1% the cases (0.2%)
    • Four adenomas or parathyroid gland hyperplasia:
      • In less than 3% to 15% of the cases
  • Parathyroid carcinoma as the cause of PHPT is extremely rare in most parts of the world (~1%)
• Most parathyroid adenomas consist of parathyroid chief cells:
  • They are usually encapsulated
  • In 50% of the cases they are surrounded by normal parathyroid tissue
• Some adenomas, nevertheless, are composed of oxyphil cells
  • These adenomas are usually larger than chief cell adenomas
• Parathyroid adenomas are sometimes located within the thymus:
  • They express a parathyroid-specific gene:
    • GCMB:
      • Contrasting with the normal thymus:
        • Which does not express neither PTH nor GCMB
• In a study by Ruda et al:
  • 20, 225 patients with PHPT:
  • Parathyroid hyperplasia accounted for approximately six percent of cases
  • In parathyroid hyperplasia all four glands are enlarged:
    • With the lower glands typically being larger than the upper ones
    • The glands are usually composed of chief cells
    • Clear cell hyperplasia is very rare:
      • And is the only form in which the upper glands are larger than the lower ones

#Arrangoiz #ParathyroidSurgeon #ParathyroidExpert #HeadandNeckSurgeon #CancerSurgeon #EndocrineSurgery #Hyperparathyroidism #MountSinaiMedicalCenter #MSMC #Miami #Mexico

• When a patient has a negative but close DCIS margin:
  • The margin width (distance between the edge of the DCIS and the inked margin) reflects the completeness of excision and is an important determinant of local recurrence in DCIS:
    • Particularly for patients considering omission of radiotherapy after breast-conserving surgery
• In 2016, the Society of Surgical Oncology and American Society of Radiation Oncology developed consensus guidelines regarding margins for DCIS:
  • These guidelines were based on a meta-analysis of 22 trials enrolling 4,660 women treated with partial mastectomy and radiation therapy:
    • There was a 64% reduction in local recurrence risk in patients with negative margins compared to those with positive margins
  • Margin thresholds ≥ 2 mm were associated with fewer local recurrences
• For patients with positive margins:
  • Either re-excision or mastectomy to achieve negative margins should be performed
• For patients with close margins, multiple factors should be considered:
  • The volume / extent of DCIS
  • Its distribution throughout a specimen
  • The volume of the excision
  • The volume of DCIS deemed close to the margin (focal or extensive)
• After review of pathology:
  • Re-excision and / or radiation boost should be performed
• A post-excision mammogram:
  • May be considered to rule out residual suspicious calcifications in the partial mastectomy operative bed for targeting during re-excision:
    • Breast-conservation therapy may be re-attempted
• If the close margins are extensive, mastectomy may be indicated
• References
  • Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Ann Surg Oncol. 2016;23(12):3801-3810.
  • Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg. 2015;262(4):623-631.
  • Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27(10):1615-1620.

• Based on the classic paper by Norris and others:
  • The development of the parathyroid glands in humans can be divided into five stages:
    • Preprimordial stage
    • Early primordial stage
    • Branchial complex stage
    • Isolation stage
    • Definitive form stage

• The preprimordial stage:
  • Indicates the period between the formation of the pharynx and the earliest appearance of a recognizable parathyroid anlage:
    • During this stage, at 4 mm to 8 mm in length:
      • The third and fourth pharyngeal pouches show a slight dorsal extension.
    • The third pouch:
      • Which has the form of a tubelike lateral expansion of the primitive pharynx:
        • Makes contact with the ectoderm of the pharyngeal cleft and then continues its growth in a downward and ventral direction.
• The early primordial stage:
  • When the embryo is about 9 mm in length:
    • The parathyroid tissue can be recognized
  • Proliferation and differentiation of large, clear cells occur in the third and fourth pouches:
    • Resulting in:
      • A thickening of the third and fourth pouches
      • Formation of a budlike nodule of the fourth pouch
• The branchial complex stage:
  • The derivatives of the third and fourth pharyngeal pouches become separated from each other to reach independent positions. 
  • During the early phase of this stage:
    • The pharyngeal pouches are still joined to the primitive pharynx by pharyngobranchial ducts:
      • These latter, subsequently, narrow and finally divide:
        • Which determines the definitive separation of the third and caudal pharyngeal complexes from the primitive pharynx.
    • At the beginning of this stage:
      • The primordial thymus and PIII are intimately joined:
        • Subsequently, the thymus begins a period of rapid ventral growth:
          • Until the lower pole comes in contact with the pericardium.
        • On the other hand, the growth of the PIII is not as rapid, and it remains a budlike projection from the superior end of the thymus cord.
        • Finally, it takes a sphere shape, intimately attaching to the upper pole of the thymus cord.
      • The position of the caudal pharyngeal complex in relation to the median anlage of the thyroid depends on:
        • Changes in form, size, and position of the rapidly growing lateral lobe of the median thyroid.
        • During this stage, the PIV rudiment is still attached to lateral thyroid body. 
        • When the embryo is 13 mm to 14 mm long, the PIII and PIV migrate together with the thymus and ultimobranchial bodies, respectively.
        • Because of the extension of the cervical spine and the descent of the heart and great vessels:
          • The complex derived from the third branchial (parathymus) is drawn toward the superior mediastinum and, thus:
            • Migrates in a medial and caudal direction through the entire length of the embryonic neck to reach its final position, and separation of the PIII from the thymus begins.
        • The PIV follows the thyroid migration of the ultimobranchial bodies, which travel toward the lateral part of the main median thyroid rudiment:
          • Their descent in the neck is thus relatively limited. 
          • They remain in contact with the posterior part of the middle third of the thyroid lobes.
    • The complex branchial stage ends when the embryo is approximately 18 to 20 mm in length.

• The isolation stage:
  • Is characterized by the separation of the parathyroid rudiments (PIII and PIV) from the other elements of the third (the thymus) and of the caudal pharyngeal complexes (the ultimobranchial bodies), respectively.
  • The isolation of the parathyroid glands is usually accomplished when the embryo is 20 mm in length. 
  • After completing the descent through the neck:
    • The PIII increases in size and separation from the thymus occurs, because of cephalic regression of the last.
    • PIII is thus abandoned at the level of the anterior or posterolateral region of the inferior poles of the thyroid lobes, or at the level of the thyrothymic ligaments, vestigial structures indicative of their former connections.
  • The two elements of the caudal pharyngeal complex also grow separately and are conjoined by a connecting stalk:
    • The interruption of this stalk, determining the isolation of the PIV, occurs once the lateral and the median thyroid become incorporated. 
    • The final position of the PIV in relation to the thyroid gland is determined by the place at which the inclusion of the ultimobranchial body (lateral thyroid element) occurs.
• The definitive form stage:
  • Indicates the period from the end of the isolation to the time when the parathyroids assume their definitive form.

Rodrigo Arrangoiz MS, MD, FACS a head and neck surgeon / endocrine surgeon / surgical oncologist and is a member of Mount Sinai Medical Center:

• He is an expert in the management parathyroid diseases.

• Publication on parathyroid embryology and anatomy:

  • Parathyroid Embryology, Anatomy, and Pathophysiology of Primary Hyperparathyroidism:

    • Arrangoiz, R., Cordera, F., Caba, D., Juárez, M.M., More- no, E. and Luque, E. (2017) Parathyroid Em- bryology, Anatomy, and Pathophysiology of Primary Hyperparathyroidism. International Journal of Otolaryngology and Head & Neck Surgery, 6, 39-58.https://doi.org/10.4236/ijohns.2017.64007

      • https://file.scirp.org/pdf/IJOHNS_2018071317420392.pdf

Training:

• General surgery:

• Michigan State University:

• 2004 al 2010

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:

• Fox Chase Cancer Center (Filadelfia):

• 2010 al 2012

• Masters in Science (Clinical research for health professionals):

• Drexel University (Filadelfia):

• 2010 al 2012

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:

• IFHNOS / Memorial Sloan Kettering Cancer Center:

• 2014 al 2016

#Arrangoiz

#Teacher

#Surgeon

#Cirujano

#ThyroidExpert

#ThyroidSurgeon

#CirujanodeTiroides

#ExpertoenTiroides

#ExpertoenParatiroides

#Paratiroides

#Hiperparatiroidismo

#PapillaryThyroidCancer

#SurgicalOncologist

#CirujanoOncologo

#CancerSurgeon

#CirujanodeCancer

#HeadandNeckSurgeon

#CirugiaEndocrina

#EndocrineSurgery

#CirujanodeCabezayCuello

• Clinical hallmarks of Paget’s disease of the breast include:
  • Scaling
  • Erythema
  • Ulceration of the nipple:
    • Sometimes extending to the areola
• Because the main differential diagnosis for this clinical presentation is eczema:
  • A short course of topical steroids was an appropriate initial step:
    • Failure to resolve should prompt tissue biopsy by punch or wedge technique and not additional steroid therapy
• Pathology:
  • Revealing adenocarcinoma cells within the epidermis (Paget cells):
    • Confirms the diagnosis
• HER2 amplification is found in 60% to 90% of cases of Paget’s disease of the breast:
  • But the patient should be fully evaluated prior to making decisions regarding the need for targeted therapy
• Appropriate diagnostic imaging includes:
  • Mammography
  • Ultrasound
  • Breast MRI (when indicated)
    • As Paget’s disease is associated with an underlying malignancy 85% of the time
• The appropriate surgical management of Paget’s disease is:
  • Breast conservation with central mastectomy (resection of the nipple-areolar complex) with resection of the primary tumor and irradiation or mastectomy, and not duct exploration
• References
  • Chen CY, Sun LM, Anderson BO. Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S. Cancer. 2006;107(7):1448-1458.
  • Killelea BK, Chagpar AB, Horowitz NR, Lannin DR. Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011. Am J Surg. 2017;213(2):426-432.
  • Caliskan M, Gatti G, Sosnovskikh I, et al. Paget’s disease of the breast: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2008;112(3):513-521.

#Arrangoiz #BreastSurgeon #CancerSurgeon #SurgicalOncologist #MountSinaiMedicalCenter #MSMC #Miami #Mexico #BreastCancer

• The Society of Surgical Oncology-American Society for Radiation Oncology (SSO-ASTRO) 2014 Consensus Guidelines:
  • Regarding margins of resection for invasive carcinoma of the breast:
    • Recommend the use of “no ink on tumor” as the standard of care:
      • For patients with invasive cancer:
        • Even with associated ductal carcinoma in situ (DCIS), are treated according to these guidelines
• In a meta-analysis of 33 studies including 32,363 patients:
  • Odds of local recurrence were associated with margin status of positive vs. negative:
    • But not decreased with increasing margin distance for patients with invasive carcinoma
  • The study reported that rates of in-breast tumor recurrence are twice as high with positive margins:
    • Regardless of tumor biology, radiation boost, or endocrine therapy
      • There was no evidence that wide margins reduce recurrence:
        • Even in patients with extensive intraductal component
• The American Society of Clinical Oncology (ASCO) guidelines:
  • Recommend consideration of post-excision mammography to document adequate resection in patients with microcalcifications
• References
  • Moran MS, Schnitt SJ, Giuliano AE, et al. SSO-ASTRO consensus guideline on margins for breast-conserving surgery with whole breast irradiation in stage I and II invasive breast cancer. Int J Radiat Oncol Biol Phys. 2014;88(3):553-564.
  • Houssami N, Macaskill P, Marinovich ML, Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol. 2014;21(3):717-730.
  • Buchholz TA, Somerfield MR, Griggs JJ, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol.2014;32(14):1502-1506.